Novartis AG (NVS.US) anticipates currency-adjusted sales growth of 5% to 6% by 2030, driven by higher revenue expectations for its cancer treatments Kisqali and Scemblix. The pharmaceutical giant has revised upward the peak sales forecast for Kisqali, a therapy for a common form of breast cancer, from $8 billion to at least $10 billion. For Scemblix, its leukemia drug, Novartis now projects peak sales of at least $4 billion, up from the prior estimate of $3 billion. The company noted that each of its eight most promising approved drugs has potential peak sales ranging between $3 billion and $10 billion. Last month, Novartis acquired Avidity Biosciences for $12 billion to expand its pipeline of muscle disorder treatments, part of broader efforts to offset declining sales of existing products, including its heart failure drug Entresto. The acquisition is expected to boost the company's annual sales growth projection to 6% from 2024 to 2029, up from the previous 5% estimate.
Comments